Cryo-EM Structure of HIV-1 Reverse Transcriptase with <i>N</i>-Phenyl-1-(phenylsulfonyl)-1<i>H</i>-1,2,4-triazol-3-amine: A New HIV-1 Non-nucleoside Inhibitor

The use of highly active antiretroviral therapy (HAART) has made the human immunodeficiency virus (HIV) a chronic disease rather than a terminal disease. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are an important component of HAART, although we are seeing clinically relevant drug-resistant mutants such that there is a need to develop new molecules. We recently identified a new class of <i>N</i>-phenyl-1-(phenylsulfonyl)-1<i>H</i>-1,2,4-triazol-3-amine HIV-1 NNRTI, with one known as compound 12126065, with sub nanomolar (nM) potency in TZM-bl cells (HeLa cells expressing CD4, CCR5, and CXCR4) with no in vivo acute or subacute toxicity. We now describe the cryo-EM structure of this molecule (resolution of 3.53 Å) and compare it to analogues and other known NNRTIs. We also describe the synthesis and activity of five additional analogues of this class of compounds, some of which have promising activity against a K103N/Y181C (A17) double mutant, which will enable the design of future molecules.

Authors

Institutions

Publication Details

Journal
ACS Infectious Diseases
Published
2025-04-30
DOI
https://doi.org/10.1021/acsinfecdis.5c00189
Primary Topic
HIV Research and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Cryo-EM Structure of HIV-1 Reverse Transcriptase with N-Phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine: A New HIV-1 Non-nucleoside Inhibitor

Vadim Makarov, Thomas R. Lane, Geoffrey Chang, Steven D. Rees et al.
ACS Infectious Diseases
HIV Research and Treatment
article

Cryo-EM Structure of HIV-1 Reverse Transcriptase with N-Phenyl-1-(phenylsulfonyl)-1H-1,2,4-triazol-3-amine: A New HIV-1 Non-nucleoside Inhibitor

Vadim Makarov, Thomas R. Lane, Geoffrey Chang, Steven D. Rees, Elena Kazakova, Renuka Raman, Olga Riabova, Natalia Monakhova, Sean Ekins, Megan A. Young, Andrey Tsedilin, Julie A. Nelson, Daniel Quinnell
article en

Abstract

The use of highly active antiretroviral therapy (HAART) has made the human immunodeficiency virus (HIV) a chronic disease rather than a terminal disease. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) are an important component of HAART, although we are seeing clinically relevant drug-resistant mutants such that there is a need to develop new molecules. We recently identified a new class of <i>N</i>-phenyl-1-(phenylsulfonyl)-1<i>H</i>-1,2,4-triazol-3-amine HIV-1 NNRTI, with one known as compound 12126065, with sub nanomolar (nM) potency in TZM-bl cells (HeLa cells expressing CD4, CCR5, and CXCR4) with no in vivo acute or subacute toxicity. We now describe the cryo-EM structure of this molecule (resolution of 3.53 Å) and compare it to analogues and other known NNRTIs. We also describe the synthesis and activity of five additional analogues of this class of compounds, some of which have promising activity against a K103N/Y181C (A17) double mutant, which will enable the design of future molecules.

ACS Infectious DiseasesVol. 11(5)
University of California San Diego (US), Collaborations Pharmaceuticals (United States) (US), University of Montana (US)
National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Environmental Health Sciences, Center for AIDS Research, University of North Carolina at Chapel Hill
Good health and well-being
Openalex Percentile: Top 90%
HIV Research and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.